Madrigal Pharmaceuticals (MDGL) Retained Earnings (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Retained Earnings for 17 consecutive years, with -$2.2 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Retained Earnings fell 16.95% year-over-year to -$2.2 billion; the TTM figure through Jun 2026 stood at -$2.2 billion (down 16.95% YoY), while the FY2025 annual figure was -$2.1 billion, down 16.0% from the prior year.
• Retained Earnings declined to -$2.2 billion in Q2 2026 per MDGL's latest filing, from -$2.2 billion in the prior quarter.
• Across five years, Retained Earnings topped out at -$724.8 million in Q1 2022 and bottomed at -$2.2 billion in Q2 2026.
• Historically, Retained Earnings has averaged -$1.5 billion across 5 years, with a median of -$1.6 billion in 2024.
• Annual changes were most pronounced in 2022 — Retained Earnings tumbled 51.63% — and 2025, when it decreased 16.0%.
• Madrigal Pharmaceuticals' Retained Earnings stood at -$962.7 million in 2022, then sank by 38.81% to -$1.3 billion in 2023, then slumped by 34.86% to -$1.8 billion in 2024, then fell by 16.0% to -$2.1 billion in 2025, then declined by 7.29% to -$2.2 billion in 2026.
• Business Quant data shows MDGL's Retained Earnings at -$2.2 billion in Q2 2026, -$2.2 billion in Q1 2026, and -$2.1 billion in Q4 2025.